Scarica l'app Stockscreener
66.90
0.15%
0.10
Dopo l'orario di chiusura:
66.90
Precedente Chiudi:
$66.80
Aprire:
$67.35
Volume 24 ore:
65,063
Relative Volume:
1.23
Capitalizzazione di mercato:
$2.13B
Reddito:
-
Utile/perdita netta:
$-32.61M
Rapporto P/E:
-56.97
EPS:
-1.1742
Flusso di cassa netto:
-
1 W Prestazione:
+1.86%
1M Prestazione:
+0.41%
6M Prestazione:
-0.81%
1 anno Prestazione:
+37.17%
Intervallo 1D:
$64.80
$68.17
Intervallo di 1 settimana:
$64.80
$73.80
Portata 52W:
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BLTE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
66.90 | 2.19B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio (NASDAQ:BLTE) Price Target Lowered to $98.00 at HC Wainwright - MarketBeat
VolitionRX (VNRX) Gets a Hold from Benchmark Co. - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Given New $98.00 Price Target at HC Wainwright - Defense World
Belite Bio Shares Climb Amid Clinical Progress - TipRanks
Belite Bio stock price target lowered to $98 at H.C. Wainwright on share count - Investing.com
Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position - TipRanks
Belite Bio (NASDAQ:BLTE) Shares Gap UpHere's Why - MarketBeat
Using RSI to spot recovery in Belite Bio Inc Depositary ReceiptJuly 2025 Patterns & Consistent Profit Alerts - Newser
Will earnings trigger a reversal in Belite Bio Inc Depositary ReceiptEarnings Growth Summary & Low Drawdown Investment Ideas - Newser
Belite Bio completes last subject visit in phase 3 Stargardt trial - Investing.com
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
How to build a dashboard for Belite Bio Inc Depositary Receipt stock2025 Price Targets & Community Consensus Picks - Newser
Alyeska Investment Group L.P. Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio Secures $125 Million in PIPE Financing with Potential for More - MSN
Benchmark reiterates Buy rating on Belite Bio stock after $275 million PIPE - Investing.com
Belite Bio raises $125 million in private placement for eye disease drugs By Investing.com - Investing.com South Africa
Belite Bio raises $125 million in private placement for eye disease drugs - Investing.com
$275M Biotech Deal: Belite Bio Lands Major Financing for Eye Disease Treatments from Top Healthcare Funds - Stock Titan
Belite Bio (NASDAQ:BLTE) Stock Price Down 2.3%Here's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 2.3% – Here’s What Happened - Defense World
Can Belite Bio Inc Depositary Receipt maintain its current growth rateMarket Movers & Safe Entry Point Identification - خودرو بانک
Developing predictive dashboards with Belite Bio Inc Depositary Receipt data2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Does Belite Bio Inc Depositary Receipt fit your quant trading model2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Belite Bio’s Earnings Call: Progress Amid Challenges - MSN
Is Belite Bio Inc Depositary Receipt showing signs of accumulationQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan
Multi factor analysis applied to Belite Bio Inc Depositary ReceiptQuarterly Performance Summary & AI Driven Price Forecasts - Newser
Is Belite Bio Inc Depositary Receipt stock bottoming out2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio - TipRanks
Q3 EPS Estimates for Belite Bio Lowered by Leerink Partnrs - Defense World
Belite Bio FY2029 EPS Forecast Reduced by Leerink Partnrs - Defense World
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease - TipRanks
Benchmark Co. Reiterates Buy Rating on Belite Bio, Sets $80 Price Target - AInvest
Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target - Investing.com Nigeria
Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target By Investing.com - Investing.com South Africa
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc. - TipRanks
Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress - MSN
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth - TipRanks
Belite Bio's Tinlarebant: A Groundbreaking Therapy on the Cusp of Approval in Stargardt Disease and Geographic Atrophy - AInvest
Belite Bio Aims for NDA Submission by H1 2026 with Robust Cash Runway and Advancing Phase III Trials - AInvest
Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance - Investing.com Canada
Earnings call transcript: Belite Bio Q2 2025 beats EPS expectations despite losses - Investing.com Nigeria
Belite Bio Q2 2025 Earnings Call Transcript - MarketBeat
Belite Bio Shares Drop Despite Clinical Milestones - TipRanks
Belite Bio reports Q2 EPS (50c), consensus (42c) - TipRanks
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones - TipRanks
Why Belite Bio's Widening Losses Signal a High-Probability Path to Market Leadership in Retinal Therapies - AInvest
Belite Bio's Tinlarebant: A First-in-Class Therapeutic Candidate with Dual-Indication Potential in High-Value Retinal Diseases - AInvest
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - The Globe and Mail
Belite Bio, Inc. ADR: Stock Movement Explained - TipRanks
Belite Bio Announces $15 Million Direct Offering - TipRanks
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.77%
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):